Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > Articles online first > The Journal of Cardiovascular Surgery 2018 Apr 03

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

THE JOURNAL OF CARDIOVASCULAR SURGERY

A Journal on Cardiac, Vascular and Thoracic Surgery


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,179


eTOC

 

The Journal of Cardiovascular Surgery 2018 Apr 03

DOI: 10.23736/S0021-9509.18.10463-0

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Effects of chronic statin use on 30-day major adverse cardiac and cerebrovascular events after thoracic endovascular aortic repair

Sung Y. HAM 1, 2, Suk W. SONG 3, Sang B. NAM 1, 2, Soo J. PARK 1, 2, Sijin KIM 1, Young SONG 1, 2

1 Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea; 2 Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea; 3 Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea


PDF  SUPPLEMENTARY MATERIAL  


BACKGROUND: Cardiac and cerebrovascular complications are major causes of adverse outcomes following thoracic endovascular aortic repair (TEVAR). The benefits of statins have been established, but little is known about their impact on patients undergoing TEVAR. We investigated whether chronic statin use protected against early postoperative major adverse cardiac and cerebrovascular events (MACCEs) after TEVAR.
METHODS: We retrospectively reviewed 211 patients who underwent TEVAR between February 2013 and March 2017 classified into two groups, those with acute aortic syndrome (AAS, n=79) and those without (non-AAS, n=132). Patients were subdivided according to preoperative statin therapy for ≥3 months or not. The primary endpoint was 30-day MACCE, defined as myocardial infarction, stroke, arrhythmia, cardiovascular death, or cerebrovascular death. Acute kidney injury (AKI) occurrence within 48 hours was also evaluated. Multivariate logistic regression analysis was performed to identify independent risk factors for MACCEs and AKI.
RESULTS: Incidence of MACCEs (1% vs. 11%, p = 0.019) was significantly lower in the statin group than in the no-statin group in non-AAS patients. Multivariate logistic regression analysis revealed statin use (odds ratio 0.85, 95% confidence interval 0.01-0.95, p = 0.046) as an independent predictor for MACCE in non-AAS patients. The AKI incidence was significantly higher in the statin group than in the no-statin group in AAS patients (44% vs. 15%, p = 0.018).
CONCLUSIONS: In patients undergoing TEVAR, chronic statin use was associated with reduced 30-day MACCEs in non-AAS patients, but not in AAS patients. It might rather be associated with increased risk of AKI in AAS patients.


KEY WORDS: Hydroxymethylglutaryl-CoA Reductase inhibitors - Aortic disease - Aorta, thoracic - Endovascular procedure - Acute kidney injury

top of page

Publication History

Article first published online: April 3, 2018
Manuscript accepted: April 3, 2018
Manuscript received: February 23, 2018

Cite this article as

Ham SY, Song SW, Nam SB, Park SJ, Kim S, Song Y. Effects of chronic statin use on 30-day major adverse cardiac and cerebrovascular events after thoracic endovascular aortic repair. J Cardiovasc Surg 2018 Apr 03. DOI: 10.23736/S0021-9509.18.10463-0

Corresponding author e-mail

nearmyheart@yuhs.ac